Skip to main content

Animations

MJFF Publications

1581 - 1590 of 6284 Results
Title
Year
  • Year
  • 2019
  • 2018
  • 2021
  • 2018
  • 2023
  • 2024
  • 2022
  • 2017
  • 2021
  • 2020
  • Summary Details
    OPEN
    Title: Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.27807
    Best OA location URL:
    Citation Count: 27
  • Summary Details
    OPEN
    Title: Phosphorylated α‐synuclein in the retina is a biomarker of Parkinson's disease pathology severity
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.27392
    Best OA location URL:
    Citation Count: 139
  • Summary Details
    OPEN
    Title: Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28779
    Citation Count: 135
  • Summary Details
    OPEN
    Title: Activation of Nrf2 and Hypoxic Adaptive Response Contribute to Neuroprotection Elicited by Phenylhydroxamic Acid Selective HDAC6 Inhibitors
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acschemneuro.7b00435
    Best OA location URL:
    Citation Count: 34
  • Summary Details
    OPEN
    Title: Necroptosis inhibition counteracts neurodegeneration, memory decline, and key hallmarks of aging, promoting brain rejuvenation
    Journal Name: Aging Cell
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1111/acel.13814
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-024-00652-y
    Citation Count: 7
  • Summary Details
    OPEN
    Title: Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: study rationale and protocol
    Journal Name: BMC Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s12883-022-02770-7
    Citation Count: 10
  • Summary Details
    OPEN
    Title: Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide
    Journal Name: Neuron
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuron.2017.12.012
    Citation Count: 195
  • Summary Details
    OPEN
    Title: The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease
    Journal Name: European Journal of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1111/ene.14733
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.05.033
    Citation Count: 23
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.